These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19845774)

  • 1. A study of reported factor VIII use around the world.
    Stonebraker JS; Brooker M; Amand RE; Farrugia A; Srivastava A
    Haemophilia; 2010 Jan; 16(1):33-46. PubMed ID: 19845774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of reported factor IX use around the world.
    Stonebraker JS; Bolton-Maggs PH; Brooker M; Farrugia A; Srivastava A
    Haemophilia; 2011 May; 17(3):446-55. PubMed ID: 21299742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of variations in the reported haemophilia A prevalence around the world.
    Stonebraker JS; Bolton-Maggs PH; Soucie JM; Walker I; Brooker M
    Haemophilia; 2010 Jan; 16(1):20-32. PubMed ID: 19845775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community.
    Stonebraker JS; Amand RE; Nagle AJ
    Haemophilia; 2003 May; 9(3):245-50. PubMed ID: 12694513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of variations in the reported haemophilia B prevalence around the world.
    Stonebraker JS; Bolton-Maggs PH; Michael Soucie J; Walker I; Brooker M
    Haemophilia; 2012 May; 18(3):e91-4. PubMed ID: 21649801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemophilia in the developing world: successes, frustrations and opportunities.
    Tezanos Pinto M; Ortiz Z
    Haemophilia; 2004 Oct; 10 Suppl 4():14-9. PubMed ID: 15479366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.
    Bidlingmaier C; Deml MM; Kurnik K
    Haemophilia; 2006 May; 12(3):212-7. PubMed ID: 16643203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
    Manco-Johnson M
    Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemophilia care in Europe: a survey of 19 countries.
    O'Mahony B; Noone D; Giangrande PL; Prihodova L
    Haemophilia; 2011 Jan; 17(1):35-40. PubMed ID: 20722746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII therapy for hemophilia A: current and future issues.
    Aledort L; Ljung R; Mann K; Pipe S
    Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding hemophilia care in developing countries.
    O'Mahony B; Black C
    Semin Thromb Hemost; 2005 Nov; 31(5):561-8. PubMed ID: 16276465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion.
    Pesquera-Lepatan LM; Hernandez FG; Lim RD; Chua MN
    Haemophilia; 2004 Nov; 10(6):684-8. PubMed ID: 15569162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory challenges to global harmonization and expanded access to concentrates: how will regulators balance the increasing cost of new safety requirements with the desire to increase the availability of affordable product?
    Farrugia A
    Haemophilia; 2004 Oct; 10 Suppl 4():83-7. PubMed ID: 15479377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.